Multifunctional N6-methyladenosine (m6A) has been revealed to be an important epigenetic component in various physiological and pathological processes, but its role in female ovarian aging remains ...unclear. Thus, we demonstrated m6A demethylase FTO downregulation and the ensuing increased m6A in granulosa cells (GCs) of human aged ovaries, while FTO-knockdown GCs showed faster aging-related phenotypes mediated. Using the m6A-RNA-sequence technique (m6A-seq), increased m6A was found in the FOS-mRNA-3'UTR, which is suggested to be an erasing target of FTO that slows the degradation of FOS-mRNA to upregulate FOS expression in GCs, eventually resulting in GC-mediated ovarian aging. FTO acts as a senescence-retarding protein via m6A, and FOS knockdown significantly alleviates the aging of FTO-knockdown GCs. Altogether, the abovementioned results indicate that FTO in GCs retards FOS-dependent ovarian aging, which is a potential diagnostic and therapeutic target against ovarian aging and age-related reproductive diseases.
Genome‐wide association studies have linked single nucleotide polymorphisms (SNPs) near the interleukin‐28B gene to the hepatitis C virus genotype 1 (HCV‐1) response to peginterferon/ribavirin ...treatment. We aimed to explore the impact on the treatment outcomes of Asian HCV‐2 patients. We determined rs8105790, rs8099917, rs4803219, and rs10853728 to be candidate SNPs in 482 Asian HCV‐2 patients treated with the standard of care. Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94‐0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4 and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow‐up). The rs10853728 genotype did not predict RVR or SVR in HCV‐2 patients. However, patients with the rs8099917 TT genotype, in comparison with patients with GT/GG genotypes, had a significantly higher rate of achieving RVR (85.2% versus 72.0%, P = 0.017) but did have not a significantly higher rate of achieving SVR (89.4% versus 86.0%). Multivariate analysis revealed that a baseline HCV viral load <400,000 IU/mL was the strongest predictor of RVR odds ratio (OR) = 4.27, 95% confidence interval (CI) = 2.31‐7.87, P < 0.001, and this was followed by advanced liver fibrosis (OR = 0.28, 95% CI = 0.15‐0.53, P < 0.001), the carriage of the rs8099917 TT genotype (OR = 3.10, 95% CI = 1.34‐7.21, P = 0.008), and the pretreatment level of aspartate aminotransferase (OR = 0.996, 95% CI = 0.99‐1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89‐42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR. Conclusion: The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV‐2 patients. (Hepatology 2011)
Comorbidities such as hypertension could exacerbate symptoms of coronaviral disease 2019 (COVID)‐19 infection. Patients with hypertension may receive both anti‐COVID‐19 and antihypertension therapies ...when infected with COVID‐19. However, it is not clear how different classes of anti‐hypertension drugs impact the outcome of COVID‐19 treatment. Herein, we explore the association between the inpatient use of different classes of anti‐hypertension drugs and mortality among patients with hypertension hospitalized with COVID‐19. We totally collected data from 278 patients with hypertension diagnosed with COVID‐19 admitted to hospitals in Wuhan from February 1 to April 1, 2020. A retrospective study was conducted and single‐cell RNA‐sequencing (RNA‐Seq) analysis of treatment‐related genes was performed. The results showed that Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) drugs significantly increased the survival rate but the use of angiotensin‐converting enzyme inhibitor/β‐block/diuretic drugs did not affect the mortality caused by COVID‐19. Based on the analysis of four public data sets of single‐cell RNA‐Seq on COVID‐19 patients, we concluded that JUN, LST1 genes may play a role in the effect of ARB on COVID‐19‐related mortality, whereas CALM1 gene may contribute to the effect of CCB on COVID‐19‐related mortality. Our results provide guidance on the selection of antihypertension drugs for hypertensive patients infected with COVID‐19.
Background
Nonalcoholic fatty liver disease (NAFLD) is a growing health issue around the world.
Aim
This study is to investigate whether adult prevalence of NAFLD correlates with national economic ...status.
Methods
Literature search on PubMed database was conducted to identify eligible records fully published before September 2014. Gross national income (GNI) per capita was chosen to evaluate national economic status. Pearson coefficient, linear regression, and unpaired
t
test were performed in the statistical analyses.
Results
Twenty-one population-based surveys (seven in East Asia, five in South Asia, three in Middle East, and six in Europe) were included. The pooled prevalence of NAFLD was 24.24 %, and the global prevalence was positively correlated with GNI per capita (
r
= 0.4782,
P
= 0.0283). Europe witnessed a higher prevalence (28.04 %) than Middle East (12.95 %,
P
= 0.0092) and East Asia (19.24 %,
P
= 0.0083). Male presented a higher prevalence than female (
P
= 0.019), especially in Europe (
P
= 0.0132) and in Caucasians (
P
= 0.0383). Furthermore, male prevalence and rural prevalence individually were correlated with economic status (
r
= 0.5725,
P
= 0.0257 and
r
= 0.7389,
P
= 0.0060). Lastly, the urban (23.93 %) witnessed a higher prevalence than the rural or the urban + rural (12.65 %,
P
= 0.0141) in the countries of GNI per capita <$10,000.
Conclusions
This study suggested that countries with higher economic status tend to present a higher prevalence of NAFLD. It is believed to provide a distinctive epidemiologic perspective to global situation of NAFLD.
Concurrent non-alcoholic fatty liver disease (NAFLD) is common in patients with chronic HBV infection. But the impact of fatty liver on the histologic progression of HBV infection remains ...controversial. Consecutive HBV-infected patients who underwent liver biopsy between 2016 and 2021 were included. Alcohol consumption and other types of viral hepatitis were excluded. All biopsies were scored for grading and staging by Scheuer's score, and the steatosis was scored as an estimate of the percentage of liver parenchyma replaced by fat. Logistic regression analyses were applied to assess the associated factors for significant liver inflammation (G greater than or equal to 2), significant fibrosis (S greater than or equal to 2) and advanced fibrosis (S greater than or equal to 3). Among the 871 HBV-infected patients, hepatic steatosis was prevalent in 255 patients (29.28%). Significant liver inflammation was present in 461 patients (52.93%). Significant fibrosis was observed in 527 patients (60.51%), while advanced liver fibrosis was observed in 171 patients (19.63%). Patients with concomitant NAFLD were more likely to have significant liver inflammation and advanced fibrosis. Fatty liver was an independent risk factor for significant liver inflammation (OR: 2.117, 95% CI: 1.500-2.988), but it could not predict the development of fibrosis. Especially, in HBV-infected patients with persistent normal ALT (immune tolerant and inactive carrier phase), the presence of significant liver inflammation was higher in NAFLD than those without NAFLD. The prevalence of advanced liver fibrosis was higher in NAFLD than non-NAFLD only in the immune tolerant phase, while NAFLD did not increase fibrosis burden in other stages of HBV infection. We developed a predictive model for significant liver inflammation with the area under receiver operating characteristic curve (AUROC) of 0.825, and a model for significant fibrosis with the AUROC of 0.760. NAFLD is independently associated with significant liver inflammation, and increases the burden of advanced liver fibrosis in HBV-infected patients. The influence of NAFLD on the degree of liver inflammation and fibrosis is different in distinct clinical phases of chronic HBV infection.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
6.
Reply to Chan et al Zhao, Liyang; Li, Yusi; Yi, Wenjuan ...
Journal of medical virology,
January 2023, 2023-01-00, 20230101, Letnik:
95, Številka:
1
Journal Article
Recenzirano
We agree that smoking might be a risk factor for the severity of COVID‐19, but in our previous study, smoking was not so robust compared with our conclusion. Also, we strongly agreed that COVID‐19 ...patients with diabetes or other chronic diseases might worsen the situation of the disease. But these factors were out of the scope of our study and we had published other research on this topic related to diabetes. Because of the limited sample size and original medical records, our study could not cover many factors. But we wish our study will be a useful and meaningful pilot study for future studies.
AIM: To investigate the relationship between the economy and the adult prevalence of fatty liver disease(FLD) in mainland China. METHODS: Literature searches on the Pub Med and Chinese National ...Knowledge Infrastructure databases were performed to identify eligible studies published before July 2014. Records were limited to crosssectional surveys or baseline surveys of longitudinal studies that reported the adult prevalence of FLD and recruited subjects from the general population or community. The gross domestic product(GDP) per capita was chosen to assess the economic status. Multiple linear regression and Loess regression were chosen to fit the data and calculate the 95%CIs. Fitting and overfitting of the models were considered in choosing the appropriate models. RESULTS: There were 27 population-based surveys from 26 articles included in this study. The pooled mean prevalence of FLD in China was 16.73%(95%CI: 13.92%-19.53%). The prevalence of FLD was correlated with the GDP per capita and survey years in the country(adjusted R2 = 0.8736, P GDP per capita = 0.00426, P years = 0.0000394), as well as in coastal areas(R2 = 0.9196, P GDP per capita = 0.00241, P years = 0.00281). Furthermore, males 19.28%(95%CI: 15.68%-22.88%) presented a higher prevalence than females 14.1%(95%CI: 11.42%-16.61%), P = 0.0071, especially in coastal areas 21.82(95%CI: 17.94%-25.71%) vs 17.01%(95%CI: 14.30%-19.89%), P = 0.0157. Finally, the prevalence was predicted to reach 20.21% in 2020, increasing at a rate of 0.594% per year. CONCLUSION: This study reveals a correlation between the economy and the prevalence of FLD in mainland China.
Granulosa cells (GCs) play a critical role in driving the formation of ovarian follicles and building the cumulus-oocyte complex surrounding the ovum. We are particularly interested in assessing ...oocyte quality by examining the detailed gene expression profiles of human cumulus single cells. Using single-cell RNAseq techniques, we extensively investigated the single-cell transcriptomes of the cumulus GC populations from two women with normal ovarian function. This allowed us to elucidate the endogenous heterogeneity of GCs by uncovering the hidden GC subpopulation. The subsequent validation results suggest that CD24(+) GCs are essential for triggering ovulation. Treatment with human chorionic gonadotropin (hCG) significantly increases the expression of CD24 in GCs. CD24 in cultured human GCs is associated with hCG-induced upregulation of prostaglandin synthase (ARK1C1, PTGS2, PTGES, and PLA2G4A) and prostaglandin transporter (SLCO2A1 and ABCC4) expression, through supporting the EGFR-ERK1/2 pathway. In addition, it was observed that the fraction of CD24(+) cumulus GCs decreases in PCOS patients compared to that of controls. Altogether, the results support the finding that CD24 is an important mediator of ovulation and that it may also be used for therapeutic target of ovulatory disorders.
The Venus A-Valve is the first commercially approved transcatheter aortic valve in China that now holds the largest market share. ...patients being sent to Venus’ core laboratory can be considered as ...representative. The perimeter of aortic annulus was smaller than the lower bound of the sizing chart of Venus A-Valve (53 mm) in 0.1% (2/1822) of patients and greater than the upper bound (91 mm) in 7.4% (135/1822) of patients. The major findings are (a) at a mean age of 73 years, the proportion of BAV morphology in this cohort was 54%, higher than similar registries of more elderly patients in industrialized countries. (b) Type 0 subtype accounted for over 40% of BAV in China, different from the type 1 dominance seen in other registries. (c) The volume of aortic leaflet calcification was higher in Chinese patients. (d) BAV patients had a relatively larger anatomy and higher calcification volume than tricuspid aortic valve, but their annulus was less elliptical in the current cohort. (e) Type 0 subtype had a smaller but less elliptical aortic annulus and less calcification than type 1 subtype. (f) Regional differences exist in aortic root dimensions and calcification burden in China. 7 Whether it may bring clinical benefits comparing with devices of higher conformability, along with a tailored treatment strategy and device design taking characteristics of Chinese patients into consideration, warrants further research studies.
PDF
